Advancing Cancer Therapy Using Natural Compound Derivatives: Mutation Agnostic Targeting of the RAS & MAPK Cascades

Time: 12:15 pm
day: Day Two Track B AM


  • Assessing novel Pan-RAS inhibitors with a unique MoA and providing updates on the clinical development of a promising new therapeutic
  • Validating targets identified by multi-omics analysis of patient materials to enable personalize precision therapy for patients
  • Elucidating the role of atypical MAPKs in human cancers to explore targeting opportunities for enhanced treatment opportunities